#CNBC Replimune co-founder calls FDA rejection of melanoma drug ‘unfair’

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair’
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street’ to discuss the company’s next steps after the FDA denied its melanoma drug.

Thank you for your support in keeping this website running.💛

View on “Tokyo Trend News”